ArticleEClinicalMedicine2026
MGUS in Black individuals in Soweto, South Africa screened by mass spectrometry: results of the PROMISE South Africa study.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
Background: Only few studies have screened for monoclonal gammopathy of undetermined significance (MGUS) among Black Africans in sub-Saharan Africa, with mixed results. Methods: In this cross-sectional study, we enrolled 2004 Black Africans aged 40-75 years from Soweto, South Africa, from January 2021 to August 2023. Participants completed an interview-guided exposure survey, underwent height and weight measurements, and provided blood samples that were screened for MGUS by matrix-assisted laser desorption ionisation-time of flight mass spectrometry. The primary outcome was the prevalence of MGUS, assessed from blood samples collected at the participants' single study visit. Prevalence was compared to those of high-risk United States (US)-based cohorts screened by the same method. Multivariable logistic regression models evaluated associations between exposures and MGUS. Findings: Prevalences of heavy-chain and light-chain MGUS among Black Africans were 12% and 3%. MGUS prevalence among Black Africans were similar to or higher than those of high-risk populations in the US. In multivariable modelling within the South Africa cohort, human immunodeficiency virus (HIV) was associated with MGUS (odds ratio [OR], 1.67; 95% confidence interval [CI], 1.27-2.21; p < 0.001). Smoking was associated with MGUS (<20 pack-years vs never smoking: OR, 1.55; 95% CI, 1.14-2.12; p = 0.01 and ≥20 pack-years vs never smoking: OR, 1.76; 95% CI, 1.21-2.56; p = 0.003). Body mass index (BMI) of ≥30 kg/m Interpretation: Results suggest Black South Africans represent a high-risk population with an increased likelihood of having MGUS. HIV, smoking, and physical activity may contribute to prevalence patterns. Prospective studies are needed to further elucidate the role of these risk factors in MGUS development and to identify strategies for early detection, risk stratification, and prevention. Funding: Stand Up To Cancer Dream Team, Multiple Myeloma Research Foundation, and National Institutes of Health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.